ZA202100026B - Complex for enhancing immune response - Google Patents

Complex for enhancing immune response

Info

Publication number
ZA202100026B
ZA202100026B ZA2021/00026A ZA202100026A ZA202100026B ZA 202100026 B ZA202100026 B ZA 202100026B ZA 2021/00026 A ZA2021/00026 A ZA 2021/00026A ZA 202100026 A ZA202100026 A ZA 202100026A ZA 202100026 B ZA202100026 B ZA 202100026B
Authority
ZA
South Africa
Prior art keywords
complex
immune response
enhancing immune
enhancing
response
Prior art date
Application number
ZA2021/00026A
Other languages
English (en)
Inventor
Haixiang Lin
Fang Liu
Li Zha
Original Assignee
Xinfu Beijing Medical Tech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201810698033.6A external-priority patent/CN108743938B/zh
Priority claimed from CN201810700708.6A external-priority patent/CN109078180B/zh
Application filed by Xinfu Beijing Medical Tech Co Ltd filed Critical Xinfu Beijing Medical Tech Co Ltd
Publication of ZA202100026B publication Critical patent/ZA202100026B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Virology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
ZA2021/00026A 2018-06-29 2021-01-04 Complex for enhancing immune response ZA202100026B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810698033.6A CN108743938B (zh) 2018-06-29 2018-06-29 用于增强免疫响应的复合物的制备方法
CN201810700708.6A CN109078180B (zh) 2018-06-29 2018-06-29 用于增强免疫响应的复合物
PCT/CN2019/093558 WO2020001587A1 (zh) 2018-06-29 2019-06-28 用于增强免疫响应的复合物

Publications (1)

Publication Number Publication Date
ZA202100026B true ZA202100026B (en) 2021-10-27

Family

ID=68984509

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2021/00026A ZA202100026B (en) 2018-06-29 2021-01-04 Complex for enhancing immune response

Country Status (11)

Country Link
US (2) US12178871B2 (cg-RX-API-DMAC7.html)
EP (2) EP3818990A4 (cg-RX-API-DMAC7.html)
JP (2) JP7296644B2 (cg-RX-API-DMAC7.html)
KR (2) KR102631084B1 (cg-RX-API-DMAC7.html)
AU (1) AU2019296320B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020026976A2 (cg-RX-API-DMAC7.html)
CA (2) CA3105281A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021000002A (cg-RX-API-DMAC7.html)
SG (2) SG11202013185VA (cg-RX-API-DMAC7.html)
WO (2) WO2020001596A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202100026B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7296644B2 (ja) 2018-06-29 2023-06-23 信福(北京)医▲薬▼科技有限公司 免疫応答を強化するための複合物の調製方法
WO2025076078A1 (en) * 2023-10-03 2025-04-10 The General Hospital Corporation Methods of central nervous system administration of compositions comprising a cell therapy and dimethyl sulfoxide

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1056315C (zh) 1993-05-31 2000-09-13 林海祥 聚肌胞复合物免疫佐剂及含有该佐剂的疫苗
ES2259914B1 (es) 2005-03-14 2007-06-16 Advanced In Vitro Cell Technologies, S.L. Nanoparticulas de quitosano y polietilenglicol como sistema de administracion de moleculas biologicamente activas.
CN103405762A (zh) * 2005-06-08 2013-11-27 依生生物制药(新加坡)私人有限公司 以聚肌苷酸-聚胞苷酸为主的佐剂
KR101203401B1 (ko) 2005-06-08 2012-11-22 이쉥 바이오파마(싱가포르)피티이 리미티드 폴리이노신산-폴리시티딜산-기초 보조제
US20070166239A1 (en) 2006-01-13 2007-07-19 Haixiang Lin Mucosal immunogenic substances comprising a polyinosinic acid - polycytidilic acid based adjuvant
US20070166800A1 (en) 2006-01-13 2007-07-19 Haixiang Lin Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant
CN101134014A (zh) 2007-09-19 2008-03-05 天津大学 带有表面涂层的硫酸钙串珠植入型局部释药体系及制备方法
CN101293933B (zh) 2008-06-17 2011-05-04 浙江大学 聚乙二醇修饰壳寡糖脂肪酸嫁接物及制备方法和应用
CN102318740B (zh) 2011-07-15 2012-11-21 山东省农业科学院畜牧兽医研究所 复合氨基酸多维液体微乳及其制备方法
SG11201406208QA (en) 2012-05-03 2014-11-27 Janssen Sciences Ireland Uc Polyinosinic-polycytidylic acid (poly (i:c)) formulations for the treatment of upper respiratory tract infections
CN103599071B (zh) * 2013-11-08 2016-01-27 杭州美亚药业股份有限公司 一种双链聚肌胞干粉的制备方法
EP3083962B1 (en) * 2013-12-16 2021-08-18 RiboxX GmbH Double-stranded polyc:poly(g/i) rna for immunostimulation and cancer treatment
CN104434784B (zh) 2014-11-15 2017-07-04 成都天台山制药有限公司 聚肌胞注射液药物组合物和制法
CN105396130A (zh) 2015-11-10 2016-03-16 林海祥 皮氨钙佐剂及含有皮氨钙佐剂的疫苗
CN107184973A (zh) 2016-03-15 2017-09-22 中国医学科学院基础医学研究所 一种复合疫苗佐剂及其应用
CN106075431A (zh) 2016-03-23 2016-11-09 林海祥 皮氨钙联合佐剂及含有皮氨钙联合佐剂的疫苗
US10512687B2 (en) 2016-04-01 2019-12-24 Colorado State University Research Foundation Compositions and methods for enhanced innate immunity
CN107875168B (zh) * 2016-09-30 2022-03-04 广州百吉生物制药有限公司 一种免疫调节组合物在治疗恶性积液中的用途
RU2647366C1 (ru) 2017-04-12 2018-03-15 Федеральное государственное учреждение "Федеральный исследовательский центр "Фундаментальные основы биотехнологии" Российской академии наук" (ФИЦ Биотехнологии РАН) Антиагрегантное средство
CN109125264B (zh) 2017-06-19 2020-10-30 林海祥 一种抗感染抗肿瘤的粘膜免疫制剂
CN109078180B (zh) * 2018-06-29 2019-05-31 信福(北京)医药科技有限公司 用于增强免疫响应的复合物
JP7296644B2 (ja) 2018-06-29 2023-06-23 信福(北京)医▲薬▼科技有限公司 免疫応答を強化するための複合物の調製方法
CN108743938B (zh) 2018-06-29 2019-04-09 信福(北京)医药科技有限公司 用于增强免疫响应的复合物的制备方法

Also Published As

Publication number Publication date
US12226477B2 (en) 2025-02-18
KR20210025095A (ko) 2021-03-08
KR102631084B1 (ko) 2024-01-29
EP3818990A4 (en) 2022-05-04
JP7366434B2 (ja) 2023-10-23
JP2021529787A (ja) 2021-11-04
KR20210025096A (ko) 2021-03-08
AU2019296320B2 (en) 2023-10-12
SG11202013185VA (en) 2021-01-28
US20240316189A9 (en) 2024-09-26
EP3815713A4 (en) 2022-04-06
EP3818990A1 (en) 2021-05-12
JP2021529789A (ja) 2021-11-04
JP7296644B2 (ja) 2023-06-23
MX2021000002A (es) 2021-05-12
CA3105283A1 (en) 2020-01-02
SG11202013183UA (en) 2021-01-28
WO2020001587A1 (zh) 2020-01-02
CA3105281A1 (en) 2020-01-02
US12178871B2 (en) 2024-12-31
WO2020001596A1 (zh) 2020-01-02
AU2019296320A1 (en) 2021-01-28
BR112020026976A2 (pt) 2021-05-25
US20220072124A1 (en) 2022-03-10
KR102704088B1 (ko) 2024-09-09
EP3815713A1 (en) 2021-05-05
US20230210893A1 (en) 2023-07-06

Similar Documents

Publication Publication Date Title
ZA201905966B (en) Anti-lag3 antibodies
IL269000A (en) Methods for modulating an immune response
IL268517A (en) Anti-tigit antibodies
SG11202000660QA (en) Anti-tigit antibodies
ZA202002141B (en) Anti-transthyretin antibodies
LT3625259T (lt) Anti-sirpalfa antikūnai
IL257071A (en) New methods for inducing an immune response
GB201709808D0 (en) Antibodies
HUE055972T2 (hu) Anti-PD-L1 antitestek
SG10201914130VA (en) GARP-TGF-β ANTIBODIES
GB202110263D0 (en) Anti-btla antibodies
GB201621686D0 (en) Novel methods for inducing an immune response
ZA202103456B (en) Anti-alpha-synuclein antibodies
GB201720970D0 (en) Antibodies
IL271067A (en) Anti-trkb antibodies
IL273529A (en) Anti-PACAP antibody
SG11202013183UA (en) Complex for enhancing immune response
GB201806084D0 (en) Antibodies
GB201711785D0 (en) Antibodies
GB201819952D0 (en) Antibodies
GB201817313D0 (en) Antibodies
GB201817309D0 (en) Antibodies
GB201817312D0 (en) Antibodies
GB201817311D0 (en) Antibodies
GB201806099D0 (en) Galectin-10 Antibodies